

Press Release



Notice of Share Acquisition of JAPAN GLASS INDUSTRY CO., LTD.

TOKYO, April 23rd, 2021 - ASKA Pharmaceutical Holdings Co., Ltd. (Headquarters: Minato-ku, Tokyo, President and Representative Director: Takashi Yamaguchi, hereinafter "ASKA") has recently acquired more than 20% of the shares of JAPAN GLASS INDUSTRY CO., LTD. (Headquarters: Chuo-ku, Tokyo, President and Representative Director: Kazumasa Watanabe, hereinafter "JAPAN GLASS") and this transaction has made JAPAN GLASS an equity-method affiliate of us.

1. Purpose of Share Acquisition

ASKA Group is engaged in three business cores, the animal health business and the testing business, with the pharmaceutical business. On April 1, 2021, ASKA shifted to a holding company structure and is promoting its businesses with a focus on becoming a total healthcare company that looks at everything from Prevention to Testing and Diagnosis, Treatment, and Prognosis.

On the other hand, JAPAN GLASS is developing a solutions business that includes the procurement of products from countries around the world and the manufacturing of pharmaceuticals through business process outsourcing, with its main business of manufacturing and developing pharmaceutical containers, mainly amples and vials. At this time, the two companies decided to collaborate in order to further strengthen their manufacturing and quality control systems by mutually utilizing the manufacturing capabilities, technologies and expertise of pharmaceuticals that they have accumulated up to now. Through this share acquisition, we will leverage the synergies between the two companies to increase productivity while reducing costs as much as possible and provide a stable supply of high-quality pharmaceuticals with outstanding efficacy and safety.

2. Outline of Shares Acquired

Number of shares	196,000 shares (20.04%)
Acquisition cost	Not disclosed, based on confidentiality obligations in the assignment agreement.

3. Overview of JAPAN GLASS

Company name:	JAPAN GLASS INDUSTRY CO., LTD.
Headquarters	7-2, Nihonbashi-Honcho 4-chome, Chuo-ku, Tokyo
Establishment	January 18, 1946
Businesses	Manufacture and sale of pharmaceutical packaging materials and contract packaging for pharmaceutical products and in vitro diagnostic reagents
Capital	75 million yen
Net Sales (FY2020)	1,231,865 (thousand yen)

Net Income (FY2020)	54,041 (thousand yen)
Net assets (FY2020)	490,593 (thousand yen)
Total assets (FY2020)	1,121,896 (thousand yen)

4. Future Financial Outlook

The impact of share acquisition on the consolidated results of ASKA for FY2021 will be minor.

【Contact】

Corporate Planning Department, ASKA Pharmaceutical Holdings Co., Ltd.

TEL: +81-3-5484-8366